Hybridoma-based antibody development: Targeting Key Protein in Long QT Syndrome and Advancing Cardiac Research

Why Develop Antibodies for KCNQ1 ?

Also referred to as Kv7.1, KCNQ1 protein is an ion channel playing a critical role in regulating cardiac electrical activity. Mutations in KCNQ1 are linked to long QT syndrome, a cardiac disorder that may result in arrhythmias and unexpected cardiac death. KCNQ1 is a complex multi-spanning membrane protein which makes it challenging for developing targeted therapies

The University of Bern investigated KCNQ1’s role in cardiac physiology and asked for high-affinity mAbs to examine the protein’s expression. For this project, having technical knowledge is crucial, along with a thorough comprehension of antigen design, and antibody development to ensure success.

Expertise in Hybridoma Development

With over 20 years of expertise in antibody development, ProteoGenix used its proven hybridoma technology for this project, a benchmark for monoclonal antibody development. Here’s how we approached the project:

Peptide Design:

Our team designed the relevant peptide that was identified using the protein sequence of KCNQ1 from a loop between transmembrane domains 5 and 6. The peptide antigen was then conjugated to the KLH (Keyhole Limpet Hemocyanin), carrier to enhance immunogenicity.

Immunization and Hybridoma Generation:

We then immunized 5 mice, fused the spleens of the best 2, and screened the resulting library of hybridomas against the peptide.

Subcloning and Antibody Production :

We then sub-cloned the 10 best clones, followed by production in purified form of the 6 best antibodies obtained.

Antibody Characterization:

Our client then tested them, and selected the best. And asked us to characterize it. The antibody demonstrated remarkable affinity, with a KD of 9 nM, a testament that underscores the precision of our monoclonal antibody development service.

Why Choose ProteoGenix for Your Antibody Development?

At ProteoGenix, we deliver solutions to drive your scientific discoveries. Our success with the University of Bern is just one example of many, where we combine cutting-edge technology, and scientific expertise to help you achieve your specific goals.

In this type of collaboration, it is important to know that the right antigen is the foundation of successful antibody development. It also requires mastery of hybridoma technology, from immunization to subcloning, to ensure and guarantee the generation of high-quality, high-affinity mAbs.

Ready to take your project to the next level? Contact us today to learn more about our hybridoma services and how we can help you achieve your goals.